Search results for "Adjuvant"

showing 10 items of 733 documents

Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.

2005

OBJECTIVES To report the long-term follow-up of patients with locally advanced bladder cancer treated with either adjuvant combined chemotherapy with methotrexate, vinblastine, doxorubicin/epirubicin, and cisplatin (MVAC/MVEC) or no additional treatment after radical cystectomy, to examine various survival endpoints and factors associated with long-term survival. PATIENTS AND METHODS Between May 1987 and December 1990, 49 patients undergoing radical cystectomy for locally advanced bladder cancer were randomized to observation only or adjuvant systemic chemotherapy with three cycles of MVAC/MVEC (methotrexate 30 mg/m2 on day 1, 15 and 22; vinblastine 3 mg/m2 on day 2, 15 and 22; doxorubicin …

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyVinblastineDisease-Free SurvivalCystectomyAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedEpirubicinChemotherapyBladder cancerbusiness.industryHazard ratioCombination chemotherapyMiddle Agedmedicine.diseaseInterim analysisCombined Modality TherapyVinblastineSurgeryMethotrexateTreatment OutcomeUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinLymphatic MetastasisFemaleCisplatinNeoplasm Recurrence Localbusinessmedicine.drugEpirubicinFollow-Up StudiesBJU international
researchProduct

Exercise Adherence and Effect of Self-Regulatory Behavior Change Techniques in Patients Undergoing Curative Cancer Treatment: Secondary Analysis from…

2020

Introduction: Adherence to exercise interventions in patients with cancer is often poorly described. Further, it is unclear if self-regulatory behavior change techniques (BCTs) can improve exercise adherence in cancer populations. We aimed to (1) describe exercise adherence in terms of frequency, intensity, time, type (FITT-principles) and dropouts, and (2) determine the effect of specific self-regulatory BCTs on exercise adherence in patients participating in an exercise intervention during curative cancer treatment. Methods: This study was a secondary analysis using data from a Swedish multicentre RCT. In a 2×2 factorial design, 577 participants recently diagnosed with curable breast, col…

Malemedicine.medical_specialtyadjuvant treatmentexercise prescriptionphysical activitylcsh:RC254-282law.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawBehavior TherapySecondary analysismedicineHumansIn patientadherenceSjukgymnastikExercisePhysiotherapySport and Fitness Sciencesbusiness.industryIdrottsvetenskapbehavioral interventionCancerProstatic NeoplasmsBehavior change methodsResistance Training030229 sport scienceslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseCancer treatmentPeer reviewExercise TherapyComplementary and alternative medicineVDP::Medisinske Fag: 700::Helsefag: 800030220 oncology & carcinogenesisExercise and Cancer TreatmentoncologyPhysical therapyExercise prescriptionbusinessResearch Articlebehavior change support
researchProduct

Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of li…

2006

Abstract Background The incidence of local reactions to diphtheria-, tetanus and acellular pertussis (DTaP-) vaccines in infants and toddlers increases with each subsequent dose, and entire thigh swellings (ETS) have been reported. Lowering the amount of antigen or of adjuvant may decrease the reactogenicity of DTaP while maintaining a protective immune response. Objectives Following priming with three doses of a DTaP vaccine during infancy, the safety, reactogenicity and immunogenicity of nine different candidate DTaP-vaccines with reduced amounts of antigen and/or adjuvant given as fourth (booster) dose were evaluated. Methods Study participants were healthy infants aged 15–27 months at t…

Malemedicine.medical_specialtymedicine.medical_treatmentDose-Response Relationship ImmunologicImmunization SecondaryBooster doseDiphtheria-Tetanus-acellular Pertussis VaccinesAdjuvants ImmunologicDouble-Blind MethodAntigenInternal medicineHumansMedicineAntigens BacterialReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryTetanusImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationInfectious DiseasesChild PreschoolImmunologyMolecular MedicineFemalebusinessAdjuvantVaccine
researchProduct

The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer tre…

2015

Objectives To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients and methods In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette–Gu erin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical out…

Malemedicine.medical_treatment030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineImmunologicRetrospective Studiehigh gradere-TURHazard ratioMiddle Agedmedicine.anatomical_structureAdministration IntravesicalTreatment Outcome030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]CohortUrinary Bladder NeoplasmBCG VaccineUrologic Surgical Proceduresbladder cancerFemaleHumanReoperationmedicine.medical_specialtyrecurrenceUrologyUrologyT1G3CystectomyArticleCystectomy03 medical and health sciencesbladder cancer; high grade; progression; re-TUR; recurrence; T1G3; UrologyAdjuvants ImmunologicUrethramedicineHumansAdjuvantsT1G3; bladder cancer; high grade; progression; re-TUR; recurrenceRetrospective StudiesAgedNeoplasm StagingBladder cancerbusiness.industryCancerRetrospective cohort studymedicine.diseaseSurgerybladder cancer; high grade; progression; re-TUR; recurrence; T1G3; Adjuvants Immunologic; Aged; BCG Vaccine; Cystectomy; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Reoperation; Retrospective Studies; Treatment Outcome; Urethra; Urinary Bladder Neoplasms; UrologyUrethraUrinary Bladder NeoplasmsprogressionNeoplasm GradingbusinessBCG vaccine
researchProduct

Neuroimmune and Mu-Opioid Receptor Alterations in the Mesocorticolimbic System in a Sex-Dependent Inflammatory Pain-Induced Alcohol Relapse-Like Rat …

2021

Evidence concerning the role of alcohol-induced neuroinflammation in alcohol intake and relapse has increased in the last few years. It is also proven that mu-opioid receptors (MORs) mediate the reinforcing properties of alcohol and, interestingly, previous research suggests that neuroinflammation and MORs could be related. Our objective is to study neuroinflammatory states and microglial activation, together with adaptations on MOR expression in the mesocorticolimbic system (MCLS) during the abstinence and relapse phases. To do so, we have used a sex-dependent rat model of complete Freund’s adjuvant (CFA)-induced alcohol deprivation effect (ADE). Firstly, our results confirm that only CFA-…

Malemedicine.medical_treatmentFreund's AdjuvantReceptors Opioid mualcohol deprivation effectNitric Oxide Synthase Type IImicroglianeuroinflammationRats Sprague-DawleyRecurrenceLimbic SystemImmunology and AllergypainPhosphorylationReceptormedia_commonMicrogliaAlcohol AbstinencealcoholMicrofilament ProteinsNF-kappa BBrief Research ReportInterleukin 10AlcoholismCytokinemedicine.anatomical_structureCytokinesFemaleμ-opioid receptorInflammation Mediatorsmedicine.medical_specialtyNeuroimmunomodulationmedia_common.quotation_subjectImmunologyPrefrontal CortexSex FactorsDownregulation and upregulationInternal medicinemedicineAnimalsNeuroinflammationbusiness.industryCalcium-Binding ProteinsAbstinenceRC581-607EndocrinologyCyclooxygenase 2mu-opioid receptorImmunologic diseases. AllergybusinessFrontiers in Immunology
researchProduct

The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer

2016

BACKGROUND Potential differences in efficacy of different bacillus Calmette-Guerin (BCG) strains are of importance for daily practice, especially in the era of BCG shortage. OBJECTIVE To retrospectively compare the outcome with BCG Connaught and BCG TICE in a large study cohort of pT1 high-grade non-muscle-invasive bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS Individual patient data were collected for 2,451 patients with primary T1G3 tumors from 23 centers who were treated with BCG for the first time between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Using Cox multivariable regression and adjusting for the most important prognostic factors in this nonrandomiz…

Malemedicine.medical_treatmentIntravesical drug administration030232 urology & nephrologyKaplan-Meier EstimateBCG ConnaughtSettore MED/24 - Urologia0302 clinical medicineMaintenance therapyMedicine610 Medicine & healthhigh gradeAged 80 and overHazard ratioMiddle AgedAdministration IntravesicalTreatment OutcomeOncology030220 oncology & carcinogenesisCohortbladder cancerFemaleImmunotherapyNon muscle invasivemedicine.medical_specialtyrecurrenceUrologyBCG Connaught; BCG Tice; BCG vaccine; bladder cancer; high grade; Immunotherapy; Intravesical drug administration; progression; recurrence; T1G3; Oncology; UrologyT1G3ArticleMaintenance ChemotherapyBCG Connaught03 medical and health sciencesAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]HumansNeoplasm InvasivenessBCG vaccineAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryImmunotherapy ActiveBCG TiceImmunotherapymedicine.diseaseSurgeryUrinary Bladder NeoplasmsDrug EvaluationprogressionNeoplasm GradingbusinessBCG vaccineFollow-Up StudiesBCG Connaught; BCG Tice; BCG vaccine; Immunotherapy; Intravesical drug administration; T1G3; bladder cancer; high grade; progression; recurrenceUrologic Oncology: Seminars and Original Investigations
researchProduct

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer

2018

PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.8…

Malemedicine.medical_treatmentPrognosis.030232 urology & nephrologyComorbidityGastroenterologySettore MED/24 - Urologia0302 clinical medicineBladder cancer; Body mass index; Obesity; PrognosisMedicineBody mass indexAged 80 and overHazard ratioBladder cancerCystoscopyMiddle AgedPrognosisTumor BurdenAdministration IntravesicalEditorialTransitional cell carcinomaChemotherapy Adjuvant030220 oncology & carcinogenesisBCG VaccineDisease ProgressionFemalemedicine.medical_specialtyPrognosiUrologyCystectomyDisease-Free SurvivalCystectomy03 medical and health sciencesAdjuvants ImmunologicInternal medicineHumansObesityMortalityAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCancer stagingCarcinoma Transitional CellBladder cancer; Body mass index; Obesity; Prognosis; UrologyScience & TechnologyBladder cancerbusiness.industryProportional hazards modelmedicine.diseaseUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisbusinessBody mass index
researchProduct

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

2021

AbstractThe current study aims to compare injectable and oral first-line disease-modifying therapies (DMTs) for time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation using a cohort of relapsing remitting multiple sclerosis (RRMS) patients, with data extracted from the Italian MS Register. This multicenter, observational, retrospectively acquired, and propensity-adjusted cohort study utilized RRMS-naïve patients from the Italian MS Register who started either injectable or oral first-line DMTs between January 1, 2010, and December 31, 2017, to evaluate the impact on disability outcomes in patients. Enrolled patients were divided into two groups, n…

Maleoral DMTsoral DMTAdministration OralDiseaseRelapsing-RemittingCohort Studies0302 clinical medicineImmunologicinjectable DMTPharmacology (medical)030212 general & internal medicineRegistriesSubcutaneousMiddle AgedItalyEDSS score; injectable DMTs; Multiple sclerosis; oral DMTs; real-world setting; Adjuvants Immunologic; Administration Oral; Adult; Cohort Studies; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Injections Subcutaneous; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; RegistriesAdministrationCohortSettore MED/26 - NeurologiaOriginal ArticleFemaleNeurosurgeryCohort studyOralAdultmedicine.medical_specialtyEDSS scoreInjections SubcutaneousLower riskInjectionsMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicInternal medicinereal-world settingmedicineHumansImmunologic FactorsMultiple sclerosiAdjuvantsinjectable DMTsRetrospective StudiesPharmacologybusiness.industryMultiple sclerosisGlatiramer AcetateInterferon-betamedicine.diseaseDiscontinuationObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Immuno-toxicological Evaluation of the Adjuvant Formulations for Experimental Anti-meningococcal Vaccines without Aluminium Hydroxide

2019

International audience; The proteoliposomes and cochleates are used as adjuvants for vaccines since they are potent immune stimulators. However, the hyper stimulation of the immune system provoked by adjuvants can cause immunetoxicological side effects. The present study was carried out to evaluate the toxic and immuno-toxicological effects of new adjuvants for anti-meningococci vaccines based on neo-proteoliposomes (nPL) and neocochleates (nCh), in Balb/c mice that were administered doses of 15 µg each, over periods of 14 days through intramuscular route and three inoculations with the same doses through intranasal route, every 7 days. The Scanning and Transmission Electron Microscopy show…

Materials Science (miscellaneous)medicine.medical_treatmentcochleatesSpleenStimulationMeningococcal vaccineImmunotoxicologyPharmacology010402 general chemistry01 natural sciencesGeneral Biochemistry Genetics and Molecular BiologyImmune systemproteoliposomesMaterials ChemistryMedicineGeneral Pharmacology Toxicology and Pharmaceuticsbusiness.industryProcess Chemistry and TechnologyGeneral EngineeringGeneral ChemistryGeneral Medicine0104 chemical sciences3. Good healthimmunotoxicologymedicine.anatomical_structureadjuvantsToxicity[SDE]Environmental SciencesNasal administrationnanoparticlesbusinessAdjuvant
researchProduct

In vitrouptake of lysozyme-loaded liposomes coated with chitosan biopolymer as model immunoadjuvants

2009

Chitosan binds to negatively charged soy lecithin liposomes by an electrostatic interaction driven by its cationic amino group. This interaction allows developing stable coated vesicles suitable as a targeted carrier and controlled release system for drugs and vaccines. In this work, we studied the effect of chitosan-coated liposomes on the uptake and antigen presentation of hen egg-white lysozyme (HEL) in Peyer's patches peritoneal macrophages isolated from mice. Chitosan-coated liposomes were characterized according to size, zeta potential, and antigen-loading and release properties. Results showed an increase in the positive net charge and size of the liposomes as the concentration of ch…

Materials sciencePolymersCoated vesiclePharmaceutical Scienceengineering.materialChitosanchemistry.chemical_compoundMicePeyer's PatchesBiopolymersDrug Delivery SystemsAdjuvants ImmunologicCationsZeta potentialFluorescence microscopeAnimalsLiposomeChitosanChromatographyMicroscopy Confocaltechnology industry and agricultureControlled releasechemistryMicroscopy FluorescenceLiposomesengineeringInterleukin-2FemaleMuramidaseBiopolymerLysozymeJournal of Liposome Research
researchProduct